Xiaolan Gu

Xiaolan Gu

Auto-generated profile, based on publicly available information

Xiaolan Gu

Department of Anesthesiology, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SWSiwei Wang
Siwei Wang
ZXZhijun Xia
Zhijun Xia
JYJing You
Jing You
XGXiaolan Gu
Xiaolan Gu
FMFanchen Meng
Fanchen Meng
RYRong Yin
Rong Yin
Currently, approximately 30%–55% of the patients with non–small cell lung cancer (NSCLC) develop recurrence due to minimal residual disease (MRD) after receiving surgical resection of the tumor. This study aims to develop an ultrasensitive and affordable fragmentomic assay for MRD detection in patients with NSCLC. A total of 87 patients with NSCLC, who received curative surgical resections (23 patients relapsed during follow-up), enrolled in this study. A total of 163 plasma samples, collected at 7 days and 6 months postsurgical, were used for both whole-genome sequencing (WGS) and targeted sequencing. WGS-based cell-free DNA (cfDNA) fragment profile was used to fit regularized Cox regression models, and leave-one-out cross-validation was further used to evaluate models’ performance. The models showed excellent performances in detecting patients with a high risk of recurrence. At 7 days postsurgical, the high-risk patients detected by our model showed an increased risk of 4.6 times, while the risk increased to 8.3 times at 6 months postsurgical. These fragmentomics determined higher risk compared with the targeted sequencing–based circulating mutations both at 7 days and 6 months postsurgical. The overall sensitivity for detecting patients with recurrence reached 78.3% while using both fragmentomics and mutation results from 7 days and 6 months postsurgical, which increased from the 43.5% sensitivity by using only the circulating mutations. The fragmentomics showed great sensitivity in predicting patient recurrence compared with the traditional circulating mutation, especially after the surgery for early-stage NSCLC, therefore exhibiting great potential to guide adjuvant therapeutics. Significance: The circulating tumor DNA mutation-based approach shows limited performance in MRD detection, especially for landmark MRD detection at an early-stage cancer after surgery. Here, we describe a cfDNA fragmentomics–based method in MRD detection of resectable NSCLC using WGS, and the cfDNA fragmentomics showed a great sensitivity in predicting prognosis.

16 May 2023
Verified
Other
Open access
SWSiwei Wang
Siwei Wang
ZXZhijun Xia
Zhijun Xia
JYJing You
Jing You
XGXiaolan Gu
Xiaolan Gu
FMFanchen Meng
Fanchen Meng
RYRong Yin
Rong Yin
Different cross-validation results of Coxnet model using fragmentomics profiles

30 May 2023
Verified
Other
Open access
SWSiwei Wang
Siwei Wang
ZXZhijun Xia
Zhijun Xia
JYJing You
Jing You
XGXiaolan Gu
Xiaolan Gu
FMFanchen Meng
Fanchen Meng
RYRong Yin
Rong Yin
Different cross-validation results of Coxnet model using fragmentomics profiles

30 May 2023
Verified
Other
Open access
SWSiwei Wang
Siwei Wang
ZXZhijun Xia
Zhijun Xia
JYJing You
Jing You
XGXiaolan Gu
Xiaolan Gu
FMFanchen Meng
Fanchen Meng
RYRong Yin
Rong Yin
Currently, approximately 30%–55% of the patients with non–small cell lung cancer (NSCLC) develop recurrence due to minimal residual disease (MRD) after receiving surgical resection of the tumor. This study aims to develop an ultrasensitive and affordable fragmentomic assay for MRD detection in patients with NSCLC. A total of 87 patients with NSCLC, who received curative surgical resections (23 patients relapsed during follow-up), enrolled in this study. A total of 163 plasma samples, collected at 7 days and 6 months postsurgical, were used for both whole-genome sequencing (WGS) and targeted sequencing. WGS-based cell-free DNA (cfDNA) fragment profile was used to fit regularized Cox regression models, and leave-one-out cross-validation was further used to evaluate models’ performance. The models showed excellent performances in detecting patients with a high risk of recurrence. At 7 days postsurgical, the high-risk patients detected by our model showed an increased risk of 4.6 times, while the risk increased to 8.3 times at 6 months postsurgical. These fragmentomics determined higher risk compared with the targeted sequencing–based circulating mutations both at 7 days and 6 months postsurgical. The overall sensitivity for detecting patients with recurrence reached 78.3% while using both fragmentomics and mutation results from 7 days and 6 months postsurgical, which increased from the 43.5% sensitivity by using only the circulating mutations. The fragmentomics showed great sensitivity in predicting patient recurrence compared with the traditional circulating mutation, especially after the surgery for early-stage NSCLC, therefore exhibiting great potential to guide adjuvant therapeutics.Significance:The circulating tumor DNA mutation-based approach shows limited performance in MRD detection, especially for landmark MRD detection at an early-stage cancer after surgery. Here, we describe a cfDNA fragmentomics–based method in MRD detection of resectable NSCLC using WGS, and the cfDNA fragmentomics showed a great sensitivity in predicting prognosis.

30 May 2023
Verified
Other
Open access
SWSiwei Wang
Siwei Wang
ZXZhijun Xia
Zhijun Xia
JYJing You
Jing You
XGXiaolan Gu
Xiaolan Gu
FMFanchen Meng
Fanchen Meng
RYRong Yin
Rong Yin
Fragmentomics model prediction ahead of radiographic confirmed recurrence. Swim plot illustrating the fragmentomics model–predicted risk status, adjuvant therapy and pathologic events of cases in which relapse occurred (A) and not yet occurred (B) during the follow-up.

16 May 2023
Verified
Other
Open access
SWSiwei Wang
Siwei Wang
ZXZhijun Xia
Zhijun Xia
JYJing You
Jing You
XGXiaolan Gu
Xiaolan Gu
FMFanchen Meng
Fanchen Meng
RYRong Yin
Rong Yin
Recursive feature elimination with cross-validation of Coxnet model using fragmentomics profiles